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verse association is especially strong in CD patients and in 
children and young adults. Experimental data available from 
various mouse models of IBD confirm that live  H. pylori  infec-
tion as well as treatment with immunomodulatory mole-
cules of  H. pylori reduce clinical and histopathological IBD 
symptoms. Various proposed mechanisms involving the
tolerization of dendritic cells, the production of protective 
cytokines and the preferential induction and differentiation 
of regulatory T-cells are presented. The implications of the 
beneficial aspects of the  Helicobacter -host interaction for
 H. pylori  eradication decisions, as well as potential new ther-
apeutic options in the treatment of IBD are discussed in this 
review.  © 2016 S. Karger AG, Basel 
 Helicobacter pylori  in Health and Disease 
 Helicobacter pylori is an extremely successful pathobi-
ont of humans, infecting approximately 50% of the world 
population. It was discovered in the early 1980s  [1] and 
has since been linked to a variety of gastric and extragas-
tric disease manifestations  [2–4] .  H. pylori  resides exclu-
sively in the human stomach; animal reservoirs or other 
habitats in the human body are not known, or at least do 
not contribute measurably to its lifestyle. The bulk of the 
 H. pylori  population is found in the mucus layer overlying 
the gastric mucosa; a minor population adheres to gastric 
epithelial cells or colonizes deep down in the glands of 
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 Abstract 
 Background: Since its discovery in the early 1980s,  Helico-
bacter pylori has been linked to a variety of gastric and extra-
gastric diseases. Chronic infection with  H. pylori causes his-
tologically evident gastritis in all colonized individuals and is 
the predominant risk factor for gastric and duodenal ulcers 
as well as gastric adenocarcinoma. However, increasingly ro-
bust experimental and epidemiological evidence suggests 
that  H. pylori may at the same time be beneficial to its carri-
ers, as it efficiently prevents allergic disorders and chronic 
inflammatory conditions. The purpose of this review is to 
summarize and document the latest evidence for a possible 
inverse association of  H. pylori infection status and the risk of 
inflammatory bowel disease (IBD), as provided in both ex-
perimental and human observational studies. The patho-
genesis of IBDs, the available mouse models for these dis-
eases and the dual role of  H. pylori in health and disease are 
presented in dedicated chapters.  Summary and Key Mes-
sages: Almost all available epidemiological data suggest 
that  H. pylori infection is inversely associated with both 
Crohn’s disease (CD) and ulcerative colitis in European, Asian 
as well as American populations; large meta-analyses re-
viewing 30 original articles or more document that this in-
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both the antrum and the corpus of the stomach  [2] .  H. 
pylori  causes histologically evident gastritis in all its car-
riers  [1] , which however remains asymptomatic in the 
majority of infected individuals  [4] . Estimates of the frac-
tions of carriers with clinical symptoms range from 5 to 
20% of an infected population. Chronic  H. pylori  infec-
tion can result in peptic ulcers (both gastric and duode-
nal) and is the single most important risk factor for the 
development of gastric adenocarcinoma and gastric B-
cell lymphoma, the so-called mucosa-associated lym-
phoid tissue lymphoma  [4–9] . The underlying causes for 
the differential disease risk of carriers remain incom-
pletely understood: bacterial virulence factors, host ge-
netic predisposition and environmental factors such as 
lifestyle and diet all appear to contribute to an individual 
carrier’s risk of developing disease  [3, 4] .  H. pylori  strains 
expressing virulence factors such as the cytotoxin-associ-
ated gene A (CagA) and the Cag pathogenicity island, as 
well as toxic versions of the vacuolating cytotoxin (VacA) 
have been linked more tightly than Cag/VacA-negative 
strains to peptic ulcer disease and gastric cancer  [3, 4] . 
Human polymorphisms affecting the baseline expression 
of key proinflammatory cytokines, as well as many other 
genes governing the host/pathogen interplay, also affect 
gastric cancer risk  [10] . More recently, the asymptomatic 
carrier state versus clinically evident disease have been at-
tributed to the strength and polarization of  H. pylori -spe-
cific T-cell responses: carriers with peptic ulcer disease 
are more likely to launch T-helper 1 (Th1)-and Th17-bi-
ased responses to  H. pylori , whereas asymptomatic car-
riers exhibit regulatory T-cell (Treg)-predominant re-
sponses  [11] . Similarly, children who typically are asymp-
tomatic even in the face of high level colonization are 
more likely to generate Treg-dominated anti- Helicobac-
ter responses than (symptomatic) adults  [12, 13] . In ex-
perimental animals, the differential responses of young 
and adult mice mirror the observations made in humans 
and have been linked to the development of Treg-medi-
ated peripheral immune tolerance  [14] . Immune toler-
ance to antigens (foreign as well as autoantigens) devel-
ops during a privileged neonatal time window during 
which both mice and humans are predisposed to tolero-
genic over immunogenic immune responses  [15] . Early 
exposure to  H. pylori thus promotes immune tolerance 
over immunity according to this model. As a conse-
quence, neonatally infected mice are largely protected 
against the characteristic Th1- and Th17-driven gastric 
immunopathology that virulent strains elicit in mice, and 
that is reminiscent of the gastric preneoplastic pathology 
of (symptomatic) infected humans  [14] . As humans typi-
cally acquire their  H. pylori strains from their mothers 
during early childhood  [16] , the same concept may very 
well apply to humans. This notion would be consistent 
with the Treg-predominant responses to  H. pylori mea-
sured in children  [12, 13] , as well as with several other 
observations related to costs and benefits associated with 
 H. pylori  infection in children relative to adults (see be-
low).
 The prevalence of  H. pylori  infection has decreased dra-
matically in the 20th century, with childhood acquisition 
rates dropping from >50 to 10% between its beginning and 
end  [17] .  H. pylori prevalence thus parallels that of other 
infectious diseases  [18] . A clear beneficial effect of this 
trend has been the steady decline in gastric cancer rates 
and associated mortality in countries from which  H. py-
lori has disappeared  [19] . However, in the same time 
frame, the incidence of immune system-mediated disor-
ders such as multiple sclerosis and type I diabetes as pro-
totypical autoimmune diseases, inflammatory bowel dis-
eases (IBDs), asthma and other allergies has dramatically 
increased  [18, 20] . Whether these inverse trends are mere-
ly coincidental, or causally linked, has lately been the focus 
of increasingly sophisticated epidemiological and experi-
mental research. Certain allergic disease manifestations 
were first shown almost 10 years ago to be less common in 
 H. pylori -infected relative to uninfected individuals of the 
same general population; this finding applies to allergic 
asthma, rhinitis and hay fever  [21–26] as well as to atopic 
dermatitis/eczema  [27, 28] . Children in particular appear 
to benefit from their  H. pylori  infection in the sense that 
the inverse correlation with allergy is strongest in pediatric 
cohorts  [22, 23, 25–27] . The notion that early life acquisi-
tion of H. pylori protects against allergic disease was sub-
sequently supported by experimental data in mouse mod-
els. Animals that had been experimentally infected with  H. 
pylori  during the neonatal tolerance window (which in 
mice closes at  ∼ 2 weeks of age), were protected against the 
development of airway hyperresponsiveness, pulmonary 
inflammation, eosinophilia and other parameters of aller-
gen-induced asthma  [29–32] . High-level protection was 
observed irrespective of the allergen (ovalbumin or house 
dust mite allergen) used  [29–32] . The beneficial effects of 
 H. pylori  could be linked experimentally to the induction 
of highly suppressive Tregs on the one hand  [29, 30] , and 
to certain  H. pylori immunomodulators on the other  [31] . 
The depletion of Tregs abrogated allergy protection, and 
the adoptive transfer of Tregs from the mesenteric lymph 
nodes of infected donors to naive recipients conferred al-
lergy protection to the recipients  [29] . The peripherally 
(and neonatally) induced Tregs that prevent excessive im-
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
4.
19
4 
- 1
/1
1/
20
17
 3
:3
0:
39
 P
M
 Arnold/Müller
 
Inflamm Intest Dis 2016;1:102–112
DOI: 10.1159/000445985
104
munopathology in children and asymptomatic carriers on 
the one hand (see above) thus appear to cross-protect 
against allergy on the other. Indeed, animals infected as 
adults, which develop gastritis and preneoplastic lesions 
(atrophic gastritis, intestinal metaplasia, hyperplasia) over 
time, are not nearly as well protected as their neonatally 
infected counterparts  [29] . The results thus argue in favor 
of a dual role of peripherally induced Tregs in the suppres-
sion of  H. pylori -specific, as well as allergen-specific T-cell 
responses ( fig. 1 ).
 In summary, it is by now quite clear that  H. pylori has 
both pathogenic and strong immunomodulatory proper-
ties, with the latter conferring beneficial effects to the hu-
man host. Although the  H. pylori field has been domi-
nated by the quest to understand the pathogenic traits of 
 H. pylori  and especially its procarcinogenic activities, in-
vestigating the immunomodulatory properties of  H. py-
lori  may be equally worthwhile.  H. pylori is an ancient 
member of the human gastric microbiota and has co-
evolved with humans for at least 60,000 years  [33] . Unless 
 Fig. 1. Dual role of the gastric pathobiont  H. pylori .  H. pylori ex-
clusively inhabits the gastric mucosa of humans. 10–20% of in-
fected individuals will develop one of several gastric infection-as-
sociated diseases, such as chronic gastritis and gastric ulcers 
(shown in the upper left inset), that are driven by pathogenic T cells 
polarized to express Th1 and Th17 cytokines. The majority (>80% 
of the infected population) will remain asymptomatic throughout 
life despite harboring high levels of  H. pylori (lower left inset). Both 
outcomes can be mimicked in experimentally infected mice. The 
 H. pylori persistence factors γ-glutamyl-transpeptidase (GGT) and 
VacA promote chronic infection by tolerizing DCs and thereby 
promoting Treg differentiation.  H. pylori -induced Tregs are re-
quired for the suppression of allergen-specific immune responses 
in the lung and for the alleviation of colitis symptoms in models of 
IBD (upper and lower right insets). Treg- and DC-derived IL-10 
contributes to  H. pylori -specific immunomodulation. Children 
and young adults are more likely than older hosts of  H. pylori  to 
benefit from the infection in terms of their individual allergy and 
IBD risk. MLN = Mesenteric lymph node. 
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eradicated by antibiotics, humans are colonized with the 
same strain for life in a mostly asymptomatic fashion. 
This intimate coexistence provides a context in which 
host and bacteria may profit from one another. The pro-
tection against IBD, for which there is now a large body 
of epidemiological as well as experimental evidence (see 
below), represents another facet of this interesting exam-
ple of host/bacterial mutualism.
 Pathogenesis of IBDs 
 IBDs are chronic relapsing disorders of rising inci-
dence affecting the gastrointestinal tract. The two main 
forms of IBD, Crohn’s disease (CD) and ulcerative colitis 
(UC) are characterized by intestinal inflammation and 
epithelial injury but differ by several clinical and patho-
logical features, suggesting that they represent indepen-
dent clinical entities. In CD, inflammation is discontinu-
ous and can affect any part of the gastrointestinal tract, 
although frequently restricted to the distal ileum and co-
lon. Discontinuous inflammation affecting all layers of 
the bowel wall and the presence of granulomas are char-
acteristic of the disorder. The transmural nature of in-
flammation further seems to account for many of the se-
rious complications associated with CD, including fibro-
stenosis, abscesses and fistula formation. In contrast, UC 
is confined to the superficial layer of the mucosa and ex-
pands continuously from the rectum, with progressive in-
flammation and ulceration of the distal colon in more ad-
vanced forms. Histological features of IBD further in-
clude disruption of the intestinal epithelium with goblet 
cell depletion, decreased mucus production and hyper-
plasia  [34] . Both CD and UC are associated with high 
morbidity and have a deleterious impact on the individu-
als’ quality of life, with alternating phases of clinical re-
lapse and remission. Symptoms mainly involve diarrhea, 
abdominal pain, rectal bleeding and weight loss. Thera-
peutic strategies for patients with IBD include corticoste-
roids, immunosuppressant agents and biologics targeting 
tumor necrosis factor-α  [35] . However, no treatment 
strategy is curative or free of side effects, and patients of-
ten have to undergo surgery.
 The precise etiology of IBD is still unclear, but involves 
a complex combination of host genetic, microbial and en-
vironmental factors. In particular, chronic inflammation 
seems to arise from an abnormal immune response 
against the microorganisms of the intestinal flora in ge-
netically susceptible individuals, resulting in the break-
down of intestinal homeostasis  [36] . There is evidence 
that both dysregulated innate and adaptive immune path-
ways contribute to the chronic inflammatory response in 
patients with IBD  [37] . Whereas the role of aberrant 
adaptive immune responses has been a focus of study for 
the last decades  [38–40] , recent advances arisen from ge-
nome-wide association studies and immunological stud-
ies have highlighted the central role of mucosal innate 
immune pathways in the pathogenesis of IBD, including 
epithelial permeability  [41, 42] , pathogen recognition 
 [43–45] and autophagy  [46, 47] . In healthy individuals, 
the epithelial barrier and innate mucosal immune system 
represent the first line of defense against invading patho-
gens. Alterations in epithelial barrier function result in 
the translocation of luminal antigens through the bowel 
wall, which triggers cytokine release and immune cell ac-
tivation. There is evidence that the mucous layer covering 
the intestinal epithelium also plays an important role in 
preventing bacterial incursions, as reduced mucin gene 
expression has been observed in CD patients  [48] . Simi-
larly,  MUC2 − / − mice have increased severity of colitis 
upon dextran sodium sulfate (DSS) treatment  [49] and 
are more susceptible to develop colorectal cancer  [50] .
 Besides abnormalities in innate and adaptive effector 
responses, it is well documented that defects in intestinal 
regulatory pathways are key determinants in the patho-
genesis of IBD. Tregs are characterized by the expression 
of Foxp3 and crucially contribute to intestinal homeosta-
sis by suppressing aberrant T-cell responses against mi-
crobial stimuli or dietary antigens. Tregs exert their sup-
pressive function through the release of anti-inflammato-
ry cytokines such as IL-10 and TGF-β or by preventing 
the activation and the effector function of T cells. In mice, 
experimental colitis can be induced by the transfer of na-
ive CD4 + CD45RB high T cells into T cell-deficient mice 
 [51] , and cotransfer of CD4 + CD45RB low Tregs cells pre-
vents the development of inflammation  [52] . Tregs were 
further found to be depleted in the peripheral blood of 
IBD patients with active disease while accumulating in 
the intestinal mucosa  [53, 54] . Interestingly, the majority 
of IBD patients have no defect in regulatory cells, and 
Foxp3 + Tregs in the mucosa of CD patients were able sup-
press effector T cell activity  [53] . However, there was only 
a moderate expansion of Tregs in the intestinal lesions of 
these patients besides the marked accumulation of effec-
tor T cells, suggesting that their anti-inflammatory func-
tions might be insufficient to control the exuberant effec-
tor response.
 Single nucleotide polymorphisms affecting the IL-10 
signaling pathway have been associated with the develop-
ment of a very early onset form of IBD  [55] , highlighting 
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the central role of IL-10 in the maintenance of intestinal 
homeostasis. IL-10 is produced by a variety of leukocytes, 
including T cells, B cells and myeloid cells. Mice with T 
cell-specific blockade of IL-10 spontaneously develop 
colitis  [56] , whereas macrophage-restricted IL-10 recep-
tor deficiency promotes intestinal inflammation through 
their impaired silencing by Treg-derived IL-10. The con-
version of Tregs and their ability to produce IL-10 was 
further promoted by commensal bacteria from the genus 
 Clostridium  [57] . Similarly,  Bacteroides fragilis , a member 
of the normal human microflora was shown to induce IL-
10 expression through the TLR2 signaling of polysaccha-
ride A directly on Tregs  [58] . Interestingly, both UC and 
CD patients have altered microbial communities, with re-
duced diversity in major phyla such as Firmicutes (in-
cluding  Clostridium ) and Bacteroidetes (including  B. fra-
gilis ), and increased numbers of adherent-invasive strains 
of the Enterobacteriaceae. These observations suggest a 
direct link between the presence of specific bacterial 
products and the maintenance of major anti-inflamma-
tory pathways in the gut. Changes in the human micro-
biota composition arising from modern hygienic prac-
tices and diet have been advanced to explain the rise and 
fall of several common diseases in developed countries 
 [17] and may therefore explain the increasing incidence 
of IBD in Western societies  [59] . However, whether the 
dysbiosis observed in IBD patients represents a primary 
predisposing factor or results from the combination of 
other deficiencies is still unclear.
 Mouse Models of IBD 
 Numerous mouse models of intestinal inflammation 
have been developed over the past 20 years, with a major-
ity recapitulating either acute or chronic colitis. These 
models are characterized by diverse types of inflamma-
tion in different regions of the small bowel and/or colon 
and can broadly be classified into 4 major categories: ero-
sive/chemically induced, immune-manipulated, sponta-
neous and genetically engineered models. Unfortunately, 
no one model faithfully reproduces all of the pathological 
features observed in CD or UC, but they rather comple-
ment each other in our understanding of the pathogenesis 
of human IBD. Although a comprehensive description of 
these models is outside the scope of this review and is re-
viewed elsewhere  [60] , we will briefly describe one of the 
most popular models, DSS chemically induced colitis, be-
cause it served as the predominant model in studies of  H. 
pylori ’s relationship with IBD.
 Administration of DSS in the drinking water is one of 
the most commonly used approaches for inducing IBD-
like symptoms in mice. Over the course of a week of DSS 
administration, the colonic epithelial cell layer starts to 
erode, allowing the penetration of bacterial products into 
the mucosa, which triggers inflammation. As severe in-
testinal inflammation can be observed alike in T cell- and 
B cell-deficient strains, it seems that the adaptive immune 
system does not play a major role in the early phase of this 
model  [61] . Colonic erosions and ulcers are manifested 
clinically as diarrhea, bloody stool and weight loss. The 
earliest lesions observed in DSS colitis include the loss of 
epithelial crypts and ulceration, with inflammation being 
a secondary event. Other lesions consist of edema, loss of 
goblet cells, abscesses and infiltration of leukocytes into 
the mucosa  [62] . Removal of the DSS and replacement 
with regular drinking water allows for restitution of the 
epithelial barrier integrity. This model is therefore suited 
to explore pathways involved in both the initiation of the 
inflammatory response and the intestinal healing pro-
cesses. Although most investigators administer DSS to in-
duce inflammation in an acute setting, a variation of the 
conventional model consists of cycling the administered 
DSS with water to induce chronic inflammation.
 Epidemiological Evidence Suggests an Inverse 
Association between Active  H. pylori  Infection and 
IBDs 
 Gastroenterologists have long suspected an inverse 
correlation between  H. pylori infection and IBD in its 
various manifestations. These sporadic observations by 
clinicians were first examined systematically in a series 
of observational studies initiated in the mid-1990s; of the 
roughly 10 studies published between 1994 and 2004, all 
but one documented a lower prevalence of H. pylori  in-
fection in patients with IBDs relative to an age-matched 
control population. CD as well as UC patients were less 
likely to be seropositive for  H. pylori  than healthy con-
trols; in many, but not all of the early studies, CD patients 
had an even lower prevalence of  H. pylori  infection than 
UC patients  [63–65] . The relatively low risk of  H. pylori 
 colonization in IBD patients was initially attributed to 
the previous exposure to antibiotics such as sulfasalazine 
 [63, 65] . As the spontaneous eradication of  H. pylori 
 through the use of antibiotics was indeed a possible con-
founding factor in the early studies – IBD patients are 
commonly treated with broad-spectrum antibiotics – 
control groups that had also received antibiotic treat-
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ment for conditions such as COPD, and IBD patients 
that had been treated exclusively with drugs other than 
antibiotics, were enrolled in several later, more sophisti-
cated studies  [66, 67] . Such studies with carefully selected 
control groups confirmed the lower prevalence of  H. py-
lori  infection in IBD patients, irrespective of the treat-
ments they received  [66, 67] . Several of these later studies 
further substituted  H. pylori serum IgG or IgA serology 
for the C 13 urea breath test, an accurate test for assessing 
active (as opposed to past) infection. These studies also 
unequivocally confirmed a lower prevalence of  H. pylori 
in IBD patients  [66–68] . Although all early studies were 
conducted on European populations, in which IBDs are 
much more common than in other geographical areas of 
the world, several more recent studies have confirmed 
the same trends in Asian and American populations  [69–
71] . A recent study of pediatric patients with or without 
IBD confirmed the trend seen in adults, i.e. children with 
newly diagnosed CD or UC were significantly less likely 
to harbor  H. pylori than non-IBD controls from the same 
general population  [72] . Several of the more recent stud-
ies have used multivariate logistic regression analyses to 
adjust for gender, ethnicity, age, income, ZIP code and 
other measures of socioeconomic status, but found the 
trends to hold true irrespective of these parameters  [70, 
73, 74] . A related condition termed microscopic colitis, a 
chronic inflammatory disease of the colon associated 
with watery diarrhea, was also found to be inversely as-
sociated with  H. pylori infection  [70] . The same and oth-
er studies showed that  Helicobacter -negative gastritis is 
not inversely, but rather positively associated with IBDs, 
including microscopic colitis  [70, 73] . Pediatric patient 
populations confirm this trend  [75] . Moreover, studies 
that include very large numbers of subjects, such as one 
analysis of the surgical pathology files of 65,515 patients 
(1,061 IBD patients and 64,451 controls), confirm the 
low prevalence of  H. pylori infection among patients with 
IBD and extend the findings to patients with indetermi-
nate colitis  [73] .
 Several meta-analyses of the existing observational 
studies have been conducted in recent years, either on 
specific populations, or irrespective of geographical area. 
A meta-analysis of 10 studies involving 1,299 Asian IBD 
patients and 1,817 controls from the same region showed 
infection rates of 24.9% in IBD patients relative to 48.3% 
in the controls, with a resulting pooled risk ratio for  H. 
pylori  infection in IBD patients calculated to be 0.48 (95% 
confidence interval: 0.43–0.54; p < 0.001)  [69] . Other me-
ta-analyses have reached similar conclusions: for exam-
ple, the first meta-analysis to be conducted on the topic 
in 2010 already included 23 studies (5,903 subjects in to-
tal) and found that overall, 27.1% of IBD patients had 
evidence of infection with  H. pylori compared to 40.9% of 
patients in the control group. This difference resulted in 
an estimated relative risk of  H. pylori infection in IBD
patients of 0.64 (95% confidence interval: 0.54–0.75). A 
more recent meta-analysis of 33 eligible studies that in-
cluded 4,400 IBD patients and 4,763 controls (the vast 
majority being non-Asian) found that 26.5% of IBD pa-
tients were  H. pylori positive, compared to 44.7% of indi-
viduals in the control group. These data resulted in an 
estimated risk ratio of 0.62 (95% confidence interval: 
0.55–0.71, p < 0.001)  [76] . In the most recent and most 
comprehensive meta-analysis to date (which includes 
studies published until July 2015), with data from 40 stud-
ies, CD and UC patients were evaluated together as well 
as separately  [74] . The entire study population included 
6,130 patients with IBD and 74,659 non-IBD controls. 
The overall calculated risk ratio for  H. pylori  infection was 
0.43 (95% confidence interval: 0.36–0.50, p < 1e–10)  [74] . 
Interestingly, stratification by patient age revealed an 
even lower risk ratio for pediatric populations (0.24 rela-
tive to 0.45 in adults). CD patients had a lower risk ratio 
than UC patients (0.38 relative to 0.53), and Eastern pop-
ulations had a lower risk ratio than Western populations 
(0.35 relative to 0.46)  [74] . The negative association be-
tween  H. pylori infection and IBD was found to be sig-
nificant regardless of the H. pylori  detection technique 
employed (histology, serology, urea breath test or multi-
ple techniques). The same meta-analysis found a positive 
association between infection with enterohepatic  Helico-
bacter species and  Campylobacter species and IBD, sug-
gesting that closely-related bacteria can have vastly differ-
ent effects on this disease group  [74] .
 All meta-analyses and almost all original articles cov-
ering the topic consistently find a strong negative asso-
ciation between  H. pylori colonization (irrespective of the 
detection method) and the IBDs. However, several as-
pects remain underexamined. These include the effects of 
 H. pylori eradication therapy on IBD risk: do patients ex-
hibit a higher IBD risk after successful treatment of their 
 H. pylori  infection with antibiotics? Or is the protective 
mechanism still active even after successful eradication? 
Another aspect worthy of investigation is the genetic 
makeup of the colonizing strain: do some strains protect 
better than others? Can ‘tolerance determinants’ or ‘pro-
tective determinants’ be identified that contribute to the 
reduction in IBD risk? Such detailed questions require 
mechanistic studies that ideally use various complemen-
tary models of IBD. The experimental data available to 
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judge the effects of active  H. pylori  infection on chronic 
intestinal inflammation in innate and adaptive models of 
IBD are discussed below.
 Experimental Evidence for a Protective Effect of 
 H. pylori on IBD 
 The observational studies conducted on a multitude of 
human populations strongly suggest a protective benefit 
of  H. pylori  infection against the development of IBD. 
Several pieces of experimental evidence are now available 
to support a direct contribution of  H. pylori , by way of its 
immunomodulatory activity, to protection against the 
chronic intestinal inflammation that is the main histo-
pathological hallmark of IBD. Several complementary 
models have been used to investigate protection against 
IBD by  live  H. pylori and purified components of the bac-
teria. In a first study, Higgins et al.  [77]  examined the ef-
fects of  H. pylori infection on  Salmonella typhimurium -
induced chronic colitis, a model that bears resemblance 
to CD.  H. pylori co-infection reduced the histopathologi-
cal symptoms associated with this model and suppressed 
the Th17 response to  S. typhimurium  in the mouse cecum 
 [77] . The beneficial effects could be linked to IL-10 pro-
duction in the mesenteric lymph nodes of the co-infected 
animals  [77] . Follow-up studies by the same group attrib-
uted the beneficial effects of  H. pylori to its DNA, which 
contains a high ratio of immunoregulatory to immuno-
stimulatory sequences, especially relative to other Gram-
negative bacteria such as  E. coli  [78] . As a consequence of 
the overrepresentation of immunoregulatory sequences, 
 H. pylori  DNA suppressed the activation of dendritic cells 
(DCs), which fail to produce proinflammatory cytokines 
(IL-12, type I IFN) when pulsed with  H. pylori  DNA  [78] . 
Oral administration of  H. pylori DNA was sufficient to 
protect against the histopathological symptoms of DSS-
induced colitis in acute and chronic models of the disease 
 [78] . Further work identified a specific immunoregula-
tory sequence, TTTAGGG, which is unique to  H. pylori 
 genomes, as being particularly active in suppressing DCs 
 [79] . Whether this sequence signals via TLR9, the canon-
ical toll-like receptor linked to the sensing of DNA, or 
other innate immune receptors remains to be elucidated. 
In any case, work by the same group and others has doc-
umented a role for TLR2 signaling in the suppression of 
DC activation, the induction of Treg-biased T-helper cell 
responses and protection against IBD  [30, 80] .  H. pylori 
 expresses strong TLR2 ligands that dominate the bacte-
ria’s interaction with DCs, and other innate and adaptive 
immune cell compartments, including B cells  [30, 80–82] . 
TLR2-deficient mice control  H. pylori  and other  Helico-
bacter species infections more effectively than wild type 
animals and, as a consequence of their unrestricted Th1 
and Th17 responses, develop more infection-associated 
gastritis and preneoplastic pathology  [30, 81] . TLR2 sig-
naling thus presumably drives a tolerogenic response in 
DCs that directs Treg-biased responses to  H. pylori anti-
gens and suppresses T-effector responses to the bacteria 
 [30] . The host benefits from this regulatory response due 
to protection from gastric immunopathology even in the 
face of high-level colonization  [30] . Interestingly, re-
sponses to unrelated (bystander) T-cell antigens are sup-
pressed as well, including allergen-specific and maybe 
autoantigen-specific immune responses  [29, 30, 32] . This 
finding explains why  H. pylori -infected individuals are 
less likely to develop allergic disease manifestations  [21–
24] , celiac disease  [83] and possibly autoimmune diseases 
 [84] (as well as of course IBD).
 TLR2 signaling is required for the  H. pylori -induced 
production and secretion of IL-10  [80, 82] , a well-studied 
cytokine with a plethora of anti-inflammatory and regu-
latory activities. It is also required for the priming of in-
flammasome activation, a critical event during the  H.
pylori /host interaction  [30, 85] .  H. pylori exclusively ac-
tivates the NLRP3 inflammasome; in contrast, other cy-
toplasmic innate immune sensors such as AIM2, NLRP6 
and NLRC4 do not contribute measurably to inflamma-
some and caspase-1 activation  [30, 85, 86] . NLRP3 in-
flammasome activation is preceded by a ‘priming’ event, 
which allows cells to upregulate NLRP3 transcription in 
a TLR2-dependent manner  [30, 85] . DCs lacking TLR2 
are incapable of NLRP3 transcriptional activation and 
caspase-1 auto-proteolysis and activation, and therefore 
fail to process and secrete the caspase-1-dependent cyto-
kines IL-1β and IL-18  [30, 85] . Both have critical roles in 
the H. pylori /host interaction, with IL-1β driving Th1 and 
Th17-polarized T-cell responses and  H. pylori  control, 
and IL-18 providing regulatory activity  [87] . The lack of 
mature IL-18 in particular recapitulates the phenotypes 
of TLR2 deficiency and NLRP3 deficiency: mice lacking 
either the cytokine or its receptor control  H. pylori more 
efficiently due to unrestricted Th1 and Th17 responses, 
but suffer from severe infection-associated immunopa-
thology  [32, 87] . IL-18 –/– mice and IL-18R –/– mice further 
are not protected against allergic asthma because they 
lack an essential regulatory pathway  [32] . The critical 
contribution of the TLR2/NLRP3/caspase-1/IL-18 sig-
naling axis to immune tolerance induced by  H. pylori 
hinted at a role of this pathway also in protection against 
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IBD. Indeed, confirming earlier data,  H. pylori protected 
effectively against DSS-induced colitis not only via its 
DNA as shown previously  [78] , but also in the context of 
experimental infection  [88] . Infection of mice during the 
neonatal period, when their predisposition to develop tol-
erance to foreign antigens is at its peak, alleviated DSS 
colitis symptoms later in life  [88] . The effect of live infec-
tion could be mimicked by regular doses of  H. pylori  ex-
tract, administered orally or intraperitoneally starting 
from the neonatal period onwards  [88] . The effects of
live infection and extract treatment required NLRP3 and 
IL-18, and were attributed to the production of copious 
amounts of mucus in NLRP3/IL-18-proficient animals 
 [88] . Mucus production was detectable by endoscopic 
procedures as well as at the transcriptional level (the main 
intestinal mucin is Muc2, which was strongly upregulated 
upon infection or extract treatment)  [88] , and likely ex-
plains the resistance to barrier destruction by DSS that is 
the underlying cause of colitis in this model. Overall, 
there is now more and more convincing experimental ev-
idence supporting a protective role of  H. pylori on IBD 
development. Combined with the epidemiological data in 
humans documenting an inverse correlation of IBD risk 
with  H. pylori prevalence, it appears likely that direct ef-
fects (via the regulatory activity of  H. pylori LPS, NLRP3 
ligands and potentially other immunomodulators) of  H. 
pylori  on immune cells, mainly DCs and Tregs, account 
for its beneficial effects. The results imply that the immu-
nomodulatory activity of  H. pylori  should be exploited for 
the development of rational treatment strategies, and that 
the clinical management of  H. pylori  and its associated 
diseases should take into account the beneficial effects of 
this ancient companion of humans and member of the 
gastric microbiota. The various implications of the ben-
efits of harboring  H. pylori  are discussed in more detail 
below.
 Conclusion: The Immunomodulatory Properties of 
 H. pylori Limit Gastric Immunopathology as well as 
Colitis 
 It is clear from the epidemiological and experimental 
data described above that  H. pylori is inversely associated 
with, and likely protective against, IBDs in their various 
manifestations. The same is true for certain allergic dis-
eases with respiratory tract and skin manifestations, and 
is currently debated for autoimmune diseases  [84, 88] . 
These results have two main implications: they will on the 
one hand influence decisions of when and whether to 
treat  H. pylori infections, and will on the other hand po-
tentially open up new avenues of treatment for these im-
mune-related disorders.  H. pylori is widely viewed as a 
major threat to a healthy stomach, and its eradication is 
now recommended even for asymptomatic individuals 
and even for adolescents and young adults in an effort to 
reduce the global gastric cancer burden  [89] . The various 
beneficial effects listed in this review, in addition to wide-
ly accepted studies documenting an inverse correlation of 
H. pylori  with various esophageal diseases (of allergic and 
nonallergic etiology) imply that simple ‘test and treat’ ap-
proaches fail to appreciate the complexity of the matter 
 [90–93] . While  H. pylori  clearly needs to be removed 
from patients with peptic ulcer disease and individuals at 
high risk for gastric cancer (i.e. presenting with precursor 
lesions), asymptomatic carriers should probably retain 
their  H. pylori  at least until adulthood. As children and 
adolescents benefit more than adults from colonization 
with  H. pylori , they clearly should only receive eradica-
tion therapy if gastric symptoms persist over extended 
periods of time and are unequivocally linked to the infec-
tion. In fact, it has even been hypothesized that pediatric 
populations in industrialized countries, where chances of 
natural transmission are now at a record low of <10% 
 [23] , would benefit from being artificially supplemented 
with (live)  H. pylori  in some form  [92] . Experimental data 
in both IBD and allergic asthma models imply that the 
regular administration of  H. pylori extract, or of purified 
 H. pylori  immunomodulators, confers a similar level of 
protection against these disorders and achieves a compa-
rable alleviation of symptoms as the live infection  [88, 
94] . Such intervention strategies could help to maximize 
benefits, while minimizing the risks associated with live 
infection. In conclusion, the complexity of the  H. pylori /
host interaction in its relationship to not only gastric, but 
general human health warrants more research into the 
molecular mechanisms, genetic determinants and life-
style factors involved in shaping the outcome of the inter-
action with this ancient companion of humans.
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